Therapeutics Company Announces Achievement In Abdominal Aortic Aneurysm Treatment
Altamira Therapeutics Announces Success in the Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles.
Abdominal aortic aneurysm (AAA) is a serious medical condition characterized by the localized abnormal enlargement of the abdominal aorta, the major blood vessel supplying blood to the lower part of the body. When an AAA ruptures, it poses a life-threatening situation, with more than half of patients succumbing before reaching emergency medical care. Furthermore, survivors often face severe complications and high morbidity rates. In light of these challenges, the recent preclinical study published by Altamira Therapeutics brings a glimmer of hope in the potential management and prevention of AAAs. $Altamira Therapeutics (CYTO.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment